Bay City Capital
Venture capitalSan Rafael · Seed–Late Stage · 8 people tracked
Also known as BAY CITY CAPITAL LLC
Find your way into Bay City Capital
630 people in our graph share verified history with the Bay City Capital team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Bay City Capital is a life sciences investment firm that invests across a diversified strategy from seed stage to public companies, concentrating largely on the development of breakthrough therapeutics. In this initiative it partnered with Takeda, Deerfield Management, and three leading New York research institutions (Memorial Sloan Kettering, The Rockefeller University, and Weill Cornell Medicine) to launch Bridge Medicines, a drug discovery company that funds and professionally manages early-stage academic projects from proof-of-concept through IND filing and clinical development.
Source: firm website, verified Aug 25, 2026.
Team · 8 people
from the firm's website & public directories
Founder mafia
2 people who came through Bay City Capital went on to found or lead other companies.
What they invest in
from 32 of 84 portfolio companiesBiotech ×26Healthtech ×16Medical Devices ×7Digital Health ×3Consumer ×2Deep Tech ×2AI & Machine Learning ×1Direct to Consumer ×1
HQs:United States×29Switzerland×2
Who they back
founder profiles across 13 portfolio companiesFounding team size:solo founder×42 founders×43 founders×44+ founders×1
Where their founders studiedfrom 11 founders with education data
Northwestern University ×2
What their founders studiedfrom 10 founders with field-of-study data
Economics ×2
Where their founders worked beforefrom 11 founders with career history
Receptos ×3
Investments · 84 tracked
founders shown can be your intro pathBy year:2025 · 12020 · 12019 · 12017 · 22016 · 22015 · 22014 · 211 dated
Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.
BiotechCopenhagen, US
Garrett Winslow(Executive Officer)inLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)
Board seatCarl Goldfischer· per SEC Form D
Co-investorsAccess BiotechnologyBAM ElevateCommodore CapitalEIR VenturesForbionJanus Henderson Investors+6 more
Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.
BiotechCambridge, US
James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)
BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)
Board seatCarl Goldfischer· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)RA CapitalAlexandriaArix BioscienceLundbeckfonden VenturesOrbiMed+2 more
Rezolute develops ersodetug, an intravenously administered monoclonal antibody targeting the insulin receptor to treat hypoglycemia caused by hyperinsulinism, with late-stage clinical programs in congenital hyperinsulinism and tumor-related hyperinsulinism.
BiotechLouisville, US
Sankaram Mantripragada(Executive Officer)Nevan Charles Elam(Executive Officer, Director)Morgan Lynn Fields(Executive Officer)Brian Roberts(Chief Medical Officer)Daron Evans(Chief Financial Officer)Sunil Karnawat(Chief Commercial Officer)
Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.
BiotechHealthtechBoulder, US
Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHelen Collins(Chief Medical Officer)inBen Hohl(Chief Financial Officer and Head of Corporate Development)in
Co-investors5AM VenturesOrbiMedPfizer Venture InvestmentsRoche Venture FundARCH Venture PartnersNew Enterprise Associates (NEA)+1 more
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
BiotechDigital HealthMedical DevicesSan Diego, US
Faheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSheila Gujrathi, MD(Founder)inBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)
Co-investorsARCH Venture PartnersEcoR1 CapitalFoothill VenturesNew Enterprise Associates (NEA)Samsara BioCapitalOmega Funds
Madrigal Pharmaceuticals is a biopharmaceutical company developing treatments for metabolic-associated steatohepatitis (MASH).
BiotechHealthtechMedical DevicesConshohocken, US
Rebecca Taub(Founder and Director)inMarc R. Schneebaum(Executive Officer)inPaul A. Friedman(Executive Officer, Director)inBill Sibold(President and Chief Executive Officer)inMardi Dier(Executive Vice President and Chief Financial Officer)inCarole Huntsman(Executive Vice President and Chief Commercial Officer)in
Co-investorsAvoro Capital AdvisorsForesite Capital
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)inUdayan Guha(Executive Officer)inSteven P. Cobourn(Executive Officer)inSourav Kundu(Executive Officer)inKevin Shaw(Executive Officer)in
Co-investorsCanaan PartnersLAVLilly Asia VenturesPfizer Venture InvestmentsQuan CapitalSofinnova Ventures+4 more
PTC is a global pharmaceutical company focused on the discovery, development, and commercialization of medicines for patients with rare diseases who have few or no treatment options.
BiotechHealthtechSouth Plainfield, US
Stuart W. Peltz(Executive Officer, Director)Allan S. Jacobson(Director)inAllan Jacobson(Director)inMark E. Boulding(Executive Officer)inChristine Utter(Executive Officer)inMarcio Souza(Executive Officer)in
Co-investorsLongwood Fund
Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.
BiotechDeep TechSemiconductorsSouth San Francisco, US
William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Emily Leproust(Founder)inEmily M. Leproust(Chief Executive Officer and Chair of the Board)inPatrick Finn(President and Chief Operating Officer)inAdam Laponis(Chief Financial Officer)in
Co-investors+ND Capital3E Bioventures CapitalARCH Venture PartnersAsset Management CompanyBlack Opal VenturesDentsu Ventures+8 more
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)inKatarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)
Co-investorsBain Capital Life SciencesF-Prime CapitalM VenturesMRL Ventures FundRA CapitalRiverVest Venture Partners+9 more
HealthtechSt Paul, US
Dan W Gladney(Executive Officer, Director)Scott P Youngstrom(Executive Officer)Rajesh Nihalani(Executive Officer)Peter M DeLange(Executive Officer)inPaul F Hickey(Executive Officer)inNaqeeb A Ansari(Executive Officer)
Board seatCarl Goldfischer· per SEC Form D
BiotechChelsea, US
RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)inMARK IWICKI(Executive Officer, Director)inMARTIN FREED(Executive Officer)in
BoardROB HOPFNER(Director)in
Co-investorsCanaan PartnersSofinnova VenturesLongitude CapitalOrbiMedRA Capital
Gilead Sciences is a biopharmaceutical company headquartered in Foster City, California that discovers, develops, and delivers medicines across virology, oncology, and inflammation.
BiotechHealthtechMedical DevicesNewark, US
Harold Van Wart, Ph. D.(Executive Officer, Director)Pol Boudes(Executive Officer)Charles A. McWherter, Ph. D.(Executive Officer)Sujal Shah(Executive Officer)
BoardCarl Goldfischer, M.D.(Director)Kurt von Emster(Director)in
Co-investorsAvoro Capital AdvisorsForesite CapitalVantagePoint Capital PartnersAbingworth
HealthtechMenlo Park, US
Thomas G. Wiggans(Executive Officer, Director)inEugene A. Bauer(Executive Officer, Director)Andrew Guggenhime(Executive Officer)Luis Pena(Executive Officer)Christopher Griffith(Executive Officer)
BoardFred Craves(Director)in
Co-investorsAisling CapitalCanaan PartnersForesite CapitalNew Enterprise Associates (NEA)Fidelity InvestmentsQiming Healthcare+1 more
David Minkinin
Co-investorsMillennium Technology Value PartnersThreshold Ventures
Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma.
BiotechDeep TechHealthtechSan Carlos, US
Wayne(CEO)Rachel(VP of Operations)
Co-investorsGV (Google Ventures)LAVLilly Asia Ventures
BiotechWatham, US
Kenneth Kornman(Executive Officer, Director)inStephen DiPalma(Executive Officer)
BoardJoseph Landstra(Director)Lionel Carnot(Director)Dayton Misfeldt(Director)James Weaver(Director)
Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.
BiotechDigital HealthHealthtechMedical DevicesDublin, US
Michael W. Dunne(Executive Officer, Promoter)inCorey N. Fishman(Executive Officer, Director, Promoter)inJudith M. Matthews(Executive Officer, Promoter)Jeff Schaffnit(Executive Officer)
BoardBrenton K. Ahrens(Director)Ronald M. Hunt(Director)
Co-investorsCanaan PartnersSofinnova VenturesAdvent Life SciencesFrazier Life SciencesSofinnova Venture Partners
KBP is a biotechnology research and development organization that discovers and develops new therapies for unmet medical needs.
Biotech
Co-investorsHM Venture Partners
Kezar Life Sciences is a clinical-stage biotechnology company developing small-molecule therapeutics for immune-mediated diseases and cancer.
BiotechSouth San Francisco, US
John F. Fowler(Executive Officer, Director)inChristopher J. Kirk(Executive Officer, Director)
BoardDr. Gerald Chan(Director)Dr. Jean-Pierre Sommadossi(Director)
Co-investorsChiesi VenturesPappas CapitalSolasta VenturesEcoR1 CapitalQiming Venture Partners
Nevro develops spinal cord stimulation systems for pain management, offering the Senza Trial Stimulator with high-frequency therapy options and wireless capability for patient trials and treatment.
AI & Machine LearningDigital HealthHealthtechMedical DevicesRedwood City, US
Co-investorsNew Enterprise Associates (NEA)
Nextwave Pharma markets Quillivant XR, a prescription central nervous system stimulant used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6 and older.
BiotechHealthtechNew Jersey, US
Co-investorsF-Prime CapitalSofinnova Ventures
Oculis is a biopharmaceutical company developing pharmaceutical drug products, with a focus on ophthalmic and eye disease treatments.
BiotechHealthtechMedical DevicesBoston, CH
Riad Sherif(Chief Executive Officer)in
Co-investorsBrunnur Ventures GPVI PartnersBVCFPivotal Life Sciences
Firmenich is a co-creation and innovation partner specializing in nutrition, health, and beauty ingredients and solutions.
ConsumerHealthtechNew MaterialsGeneva, CH
Gilbert Ghostinein
Co-investorsProspect Venture PartnersRho Ventures
Tetraphase Pharmaceuticals was a Watertown, MA biopharmaceutical company developing novel tetracycline antibiotics, including its lead drug Xerava (eravacycline) for multidrug-resistant bacterial infections.
BiotechWatertown, US
Guy Macdonald(Director)inLarry Edwards(Executive Officer, Director)inMaria Stahl(Executive Officer)inChristopher Watt(Executive Officer)
BoardL. Patrick Gage(Director)Keith Maher(Director)
Co-investorsF-Prime CapitalExcel Venture ManagementFlagship VenturesMediphase Venture Partners
Tria develops handheld laser devices for at-home hair removal and skincare, using laser technology similar to that used in professional clinics.
ConsumerDirect to ConsumerHardwareHealthtechWellness & FitnessDublin, US
TOBIN C. ISLAND(Executive Officer)inKEVIN J. APPELBAUM(Executive Officer, Director)inDEREK YUNG(Executive Officer)inDANIKA HARRISON(Executive Officer)inJIYOUNG CHOI(Executive Officer)CHARLES BRACHER(Director)in
Co-investorsAisling CapitalIncubic Management LLCVivo Capital
Vivaldi Biosciences develops Delta NS1 vaccines designed to protect against epidemic and pandemic viral respiratory diseases.
BiotechHealthtechMedical DevicesFort Collins, US
Peter Palese(Founder & Scientific Advisor)Adolfo García-Sastre(Founder & Scientific Advisor)Elliott Kieff(Founder & Scientific Advisor)William Wick(CEO, Board Member and Managing Director)
Co-investorsNGN Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Sidecar TherapeuticsSynGenAccriva DiagnosticsAciexAmerifit NutritionAqua Bounty TechAragon SurgicalAscendancy HealthcareBiorenBioSeekBlade TherapeuticsCadence PharmaceuticalsCalypso MedicalChemdexConatus PharmaCydanEos BiotechnologyEpizymeEpoch BiosciencesGenturaDxHyperion TherapeuticsIdev Technologies IncIncyte GenomicsIngenuity SystemsIntarcia TherapeuticsIon Torrent SystemsItamar MedicalLexLjl BiosystemsMap PharmaceuticalsMaxia PharmaMedarexMenlo TherapeuticsMerus BiopharmaNeoRxNupathe PharmaOculex PharmaceuticalsOmegatechOmiciaPanomicsPathway DxPharmakeaPharmanexPharmionPresidio PharmaProtez PharmaRadiant MedicalReliant PharmaceuticalsSembiosys GeneticsSymyx TechnologiesSynchronicity PharmaSyntonix PharmaSyrrxViractaVnus Medical TechVtesse IncXeris Pharmaceuticals
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 14
10 IPOs · 4 acquisitions · showing 13Damora TherapeuticsNASDAQ: DMRAImaraNASDAQ: ELVNAntriaBioNASDAQ: RZLTEnliven TherapeuticsNASDAQ: ELVNGossamer BioNASDAQ: GOSSMadrigalNASDAQ: MDGLNextCureNASDAQ: NXTCPtcbioNASDAQ: PTCTTwist BioscienceNASDAQ: TWSTXilio TherapeuticsNASDAQ: XLOIdev Technologies Incacq. by AbbottNextwavepharmaacq. by Tris PharmaTetraphase Pharmaceuticalsacq. by La Jolla Pharmaceutical Company
Portfolio news
latest coverage across their companiesDamora Therapeutics · seekingalpha.com · Sep 15, 2026
Madrigal · finance.yahoo.com · Sep 10, 2026
Enliven Therapeutics · tickerreport.com · Aug 21, 2026
Xilio Therapeutics · tickerreport.com · Aug 15, 2026
Imara · trysignalbase.com · Jul 24, 2026
NextCure · investing.com · Jul 15, 2026
Xeris Pharmaceuticals · tipranks.com · May 8, 2026
IPO stake values · per SEC filings · 3
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Damora Therapeutics | 4.2% | $15.00 | Oct 2020 | $15.6M |
| Enliven Therapeutics | 4.2% | $16.00 | Mar 2020 | $11.3M |
| Imara | 4.2% | $16.00 | Mar 2020 | $11.3M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Bay City Capital made?
- Bay City Capital has 84 tracked investments, 14 of which have exited, including 1 dated in the last 24 months.
- What stage does Bay City Capital invest at?
- Bay City Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is Bay City Capital's typical check size?
- Bay City Capital typically writes checks of $5M – $10M.
- What sectors does Bay City Capital focus on?
- Bay City Capital focuses on Biotech, Digital Health, Enterprise Software, Healthtech, Medical Devices.
- Where is Bay City Capital located?
- Bay City Capital is headquartered in San Rafael, US.
- Who does Bay City Capital co-invest with?
- Bay City Capital most often shares deals with New Enterprise Associates (NEA), Foresite Capital, Sofinnova Ventures, among 54 tracked co-investors.
Media · Podcasts & interviews
featuring the teamSimilar investors
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Norwest Venture Partners is an investment firm whose growth equity team backs private, profitable, fast-growing companies, providing capital and hands-on support through its 'invited guest' approach.
SpringRock Ventures is a Seattle-based venture firm investing in the convergence of healthcare and information technology, backing companies across digital health, medical devices, oral health, healthcare SaaS and related innovation.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
Alumni Ventures (AV) is a venture capital firm that co-invests alongside lead VCs in startups, backing founders with capital and access to a large investor and operator community.